Mutated or dysregulated transcription factors represent a unique class of drug targets that
mediate aberrant gene expression, including blockade of differentiation and cell death gene …

We now know that cancer is many different diseases, with great variation even within a
single histological subtype. With the current emphasis on developing personalized …

Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–
protein interaction has been pursued as a new cancer therapeutic strategy. In recent years …

Restoration of p53 activity by inhibition of the p53–MDM2 interaction has been considered
an attractive approach for cancer treatment. However, the hydrophobic protein–protein …

MDM2 is a primary cellular inhibitor of p53. It inhibits p53 function by multiple mechanisms,
each of which, however, is mediated by their direct interaction. It has been proposed that …

Blocking the oncoprotein murine double minute 2 (MDM2)–p53 protein–protein interaction
has long been considered to offer a broad cancer therapeutic strategy, despite the potential …

The p53 tumor suppressor is a potent transcription factor that plays a key role in the
regulation of cellular responses to stress. It is controlled by its negative regulator MDM2 …

Disruption of the MDM2-p53 protein-protein interaction by small-molecule inhibitors has
been highly pursued by many academic laboratories and pharmaceutical companies as a …

The p53 pathway has been shown to mediate cellular stress responses; p53 can initiate
DNA repair, cell-cycle arrest, senescence and, importantly, apoptosis. These responses …

Numerous studies have shown that non-coding RNAs play crucial roles in the development
and progression of various tumor cells. Plasmacytoma variant translocation 1 (PVT1) mainly …